Data gathered: May 4
Alternative Data for Atossa Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,369 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 258 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 64,609 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,507 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 33 | Sign up | Sign up | Sign up |
About Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
| Price | $0.86 |
| Target Price | Sign up |
| Volume | 517,330 |
| Market Cap | $110M |
| Year Range | $0.59 - $1.62 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
XTX Topco Ltd Acquires 29,560 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS)May 1 - ETF Daily News |
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen PortfolioApril 30 - GlobeNewswire |
|
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025April 29 - GlobeNewswire |
|
|
Renaissance Technologies LLC Raises Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)April 29 - ETF Daily News |
 |
Atossa Therapeutics announces issuance of U.S. patentApril 22 - Thefly.com |
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen PortfolioApril 22 - GlobeNewswire |
Insider Transactions View All
| Remmel H. Lawrence filed to buy 10,257 shares at $0.7. March 28 '25 |
| Finn Jonathan filed to buy 25,000 shares at $1.8. April 11 '24 |
| WEAVER GREGORY L filed to sell 55 shares at $0.7. November 17 '23 |
Similar companies
Read more about Atossa Therapeutics (ATOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Atossa Therapeutics?
The Market Cap of Atossa Therapeutics is $110M.
What is the current stock price of Atossa Therapeutics?
Currently, the price of one share of Atossa Therapeutics stock is $0.86.
How can I analyze the ATOS stock price chart for investment decisions?
The ATOS stock price chart above provides a comprehensive visual representation of Atossa Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Atossa Therapeutics shares. Our platform offers an up-to-date ATOS stock price chart, along with technical data analysis and alternative data insights.
Does ATOS offer dividends to its shareholders?
As of our latest update, Atossa Therapeutics (ATOS) does not offer dividends to its shareholders. Investors interested in Atossa Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Atossa Therapeutics?
Some of the similar stocks of Atossa Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.